# AstraZeneca’s Farxiga granted US Priority Review for chronic kidney disease

- Link: https://www.directorstalkinterviews.com/astrazenecas-farxiga-granted-us-priority-review-for-chronic-kidney-disease/412951643
- Published: 2021-01-06T07:36:17+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Farxiga_ (dapagliflozin) has been granted Priority Review in the US for the treatment
of new or worsening chronic kidney disease (CKD) in adults with and without type-
2 diabetes (T2D).

The Food and Drug Administration grants Priority Review to regulatory submissions
for medicines that offer significant advances over available options by demonstrating
safety or efficacy improvements, preventing serious conditions, or enhancing patient
compliance. The Prescription Drug User Fee Action date, the day the FDA targets 
for their regulatory decision, will be during the second quarter of 2021.

CKD, a condition defined by decreased kidney function, is often associated with 
a heightened risk of heart disease or stroke, or the need for dialysis or kidney
transplant.^(1-3) CKD is expected to become the world’s fifth leading cause of mortality
by 2040.^(4) Currently in the US, 37 million people are estimated to have CKD.^(
1)

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: **“This
> decision brings us a step closer to delivering this new treatment option for the
> millions of patients living with chronic kidney disease in the US. _Farxiga_ has
> the potential to be a truly transformational medicine across a breadth of diseases,
> including type-2 diabetes, heart failure with reduced ejection fraction and, if
> approved, chronic kidney disease.”

The acceptance of the regulatory submission by the FDA and the granting of Priority
Review was based on clinical evidence from the DAPA-CKD Phase III trial. The trial
showed that _Farxiga,_ on top of standard of care consisting of an angiotensin-converting
enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), reduced the risk
of the composite of worsening of renal function or risk of cardiovascular (CV) or
renal death by 39%, the primary endpoint, compared to placebo (absolute risk reduction[
ARR] 5.3%, p<0.0001) in patients with CKD Stages 2-4 and elevated urinary albumin
excretion. It also significantly reduced the risk of death from any cause by 31%(
ARR 2.1%, p=0.0035) compared to placebo.^(5) The safety and tolerability of _Farxiga_
were consistent with the well-established safety profile of the medicine.

In March 2020, an independent Data Monitoring Committee recommended the trial be
stopped early, based on its determination of overwhelming efficacy. Detailed results
from the DAPA-CKD trial were shared in August 2020 and published in The New England
Journal of Medicine.^(6)

In October 2020, _Farxiga_ received Breakthrough Therapy Designation in the US for
patients with CKD with and without T2D. In the US, _Farxiga_ is indicated as an 
adjunct to diet and exercise to improve glycaemic control in adults with T2D. In
May 2020 _Farxiga_ was approved in the US to reduce the risk of CV death and hospitalisation
for heart failure (hHF) in adults with heart failure (NYHA class II-IV) with reduced
ejection fraction (HFrEF) with and without T2D.

**Chronic kidney disease** 

CKD is a serious, progressive condition defined by decreased kidney function (shown
by reduced estimated glomerular filtration rate [eGFR] or markers of kidney damage,
or both, for at least three months)^(7) affecting nearly 850 million people worldwide,
many of them still undiagnosed.^(8) The most common causes of CKD are diabetes, 
hypertension and glomerulonephritis.^(9) CKD is associated with significant patient
morbidity and an increased risk of CV events, such as heart failure (HF) and premature
death. In its most severe form, known as end-stage kidney disease (ESKD), kidney
damage and deterioration of kidney function have progressed to the stage where dialysis
or kidney transplantation are required.^(1) The majority of patients with CKD will
die from CV causes before reaching ESKD.^(10)

**DAPA-CKD** 

DAPA-CKD was an international, multi-centre, randomised, double-blinded trial in
4,304 patients designed to evaluate the efficacy of dapagliflozin_ _10mg, compared
with placebo, in patients with CKD Stages 2-4 and elevated urinary albumin excretion,
with and without T2D. _Farxiga_ was given once daily in addition to standard of 
care consisting of an ACEi or an ARB. The primary composite endpoint was worsening
of renal function or risk of death (defined as a composite of an eGFR decline ≥50%,
onset of ESKD and death from CV or renal cause). The secondary endpoints included
the time to first occurrence of the renal composite (sustained ≥50% eGFR decline,
ESKD and renal death), the composite of CV death or hHF, and death from any cause.
The trial was conducted in 21 countries.^(6)

**_Farxiga_**

_Farxiga_ (dapagliflozin) is a first-in-class, oral, once-daily sodium-glucose co-
transporter-2 (SGLT2) inhibitor.

The research for _Farxiga_ is advancing from cardiorenal effects to prevention and
organ protection as science continues to identify the underlying links between the
heart, kidneys and pancreas. Damage to one of these organs can cause the other organs
to fail – contributing to leading causes of death worldwide, including T2D, HF and
CKD.

For nearly a decade _Farxiga_ has been an effective monotherapy and part of combination
therapy as an adjunct to diet and exercise to improve glycaemic control in adults
with T2D. Following results from the landmark DECLARE-TIMI 58 Phase III CV outcomes
trial, it is approved in adults with T2D to reduce the risk of hHF or CV death when
added to standard of care. _Farxiga_ is also the first SGLT2 inhibitor approved 
for the treatment of HFrEF in adults with and without T2D.

In August 2020, results from the DAPA-CKD Phase III trial demonstrated that _Farxiga_
achieved unprecedented reduction in the composite risk of kidney failure and CV 
or renal death in patients with CKD versus placebo, and is now the first SGLT2 inhibitor
shown to significantly prolong survival in a renal outcomes trial for this patient
population and provide organ protection. _Farxiga_ is not indicated for the treatment
of CKD.

DapaCare is a robust programme of clinical trials to evaluate the potential CV, 
renal and organ protection benefits of _Farxiga_. It includes more than 35 completed
and ongoing Phase IIb/III trials in more than 35,000 patients, as well as more than
2.5 million patient-years’ experience. It is currently being assessed in patients
with HF with preserved ejection fraction in the DELIVER Phase III trial. _Farxiga_
is also being tested in patients without T2D following an acute myocardial infarction(
MI) or heart attack in the DAPA-MI Phase III trial – a first of its kind, indication-
seeking registry-based randomised controlled trial.

**AstraZeneca in CVRM** 

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s 
three therapy areas and is a key growth driver for the Company. By following the
science to understand more clearly the underlying links between the heart, kidneys
and pancreas, AZN is investing in a portfolio of medicines for organ protection 
and improve outcomes by slowing disease progression, reducing risks and tackling
co-morbidities. The Company’s ambition is to modify or halt the natural course of
CVRM diseases and potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices and cardiovascular
health for millions of patients worldwide.

Share on:
